The Down Under medical community is excited with the emergence of retatrutide, a groundbreaking dual GIP and GLP-1 receptor showing significant results in early trials for addressing obesity. This therapy https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/